Carmustine is a cytotoxic antineoplastic agent that disrupts malignant cell proliferation by targeting DNA integrity, mitotic spindle function, or oncogenic signalling pathways critical to tumour cell survival. Its clinical activity against specific tumour histologies is governed by mechanism of action, pharmacokinetic parameters affecting tumour tissue penetration, and the pharmacodynamic relationship between intracellular drug concentration and cell kill. The genotoxic, mutagenic, and carcinogenic potential inherent to the cytotoxic mechanism places Carmustine in the highest occupational hazard category during pharmaceutical manufacturing.
The critical toxicological endpoint driving the PDE for Carmustine is selected through systematic comparison of all available study NOAELs across endpoint categories: general systemic toxicity, neurotoxicity, reproductive and developmental toxicity, genotoxicity, and carcinogenicity.
